<DOC>
	<DOCNO>NCT01178281</DOCNO>
	<brief_summary>The objective study determine whether pomalidomide safe effective reversing red blood cell ( RBC ) -transfusion-dependence person myeloproliferative neoplasm ( MPN ) -associated myelofibrosis . ( Global Study ) describe frequency anemia response pomalidomide Chinese participant MPN-associated myelofibrosis severe anemia receive REC-transfusions ( China Extension Study )</brief_summary>
	<brief_title>Phase-3 Double-Blind , Placebo-Controlled Study Pomalidomide Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis RBC-Transfusion-Dependence Myelofibrosis RBC-Transfusion-Dependence</brief_title>
	<detailed_description>Study sit China also participate China-specific , single-arm , open label extension current study . Participants myeloproliferative neoplasm ( MPN ) -associated myelofibrosis severe anemia receive red blood cell ( RBC ) -transfusions . Eligible participant receive pomalidomide ( 0.5 mg/day ) evaluate schedule parallel global study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age ≥18 year Myeloproliferativeneoplasm ( MPN ) associate myelofibrosis RBCtransfusiondependence Bone marrow biopsy within 6 month Inappropriate receive blood cell bone marrow allotransplant , erythropoietin androgenic steroid Eastern Cooperative Oncology Group ( ECOG ) performance score ≤2 . Agree follow pregnancy precaution require protocol . Agree receive counsel relate teratogenic risk pomalidomide . Agree donate blood semen . Prior blood cell bone marrow allotransplant . Use drug treat MPNassociated myelofibrosis ≤30 42 day start study drug . Treatment erythropoietin androgenic steroid ≤84 day start study drug . Anemia due reason MPNassociated myelofibrosis . Pregnant lactating female . More 10 % blast bone marrow examination 10 % blast blood consecutive measurement span least 8 week Prior history malignancy , disease study , unless subject free malignancy ≥5 year . Following exception : Carcinoma situ cervix Carcinoma situ breast Incidental histologic find prostate cancer ( T 1a T 1b use TNM [ tumor , node , metastasis ] clinical staging system ) Human Immunodeficiency Virus infection ( HIVinfection ) , active hepatitis B virus ( HBV ) active hepatitis C virus ( HCV ) infection . Prior treatment pomalidomide . Allergic reaction rash treatment thalidomide lenalidomide Any follow laboratory abnormality : Neutrophils &lt; 0.5x10^9 /L Platelets &lt; 25 x 10^9 /L Estimated glomerular filtration rate ( kidney function ) &lt; 30 mL/min/1.73m^2 Aspartate aminotransferase ( AST ) Alanine transaminase ( ALT ) &gt; 3.0 x upper limit normal Total bilirubin ≥4 x Upper Limit Normal ( ULN ) ; Uncontrolled hyperthyroidism hypothyroidism . Deep venous thrombosis ( DVT ) pulmonary embolus ( PE ) &lt; 6 month start study drug Clinicallyimportant heart disease within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Post-polycythemia vera myelofibrosis</keyword>
	<keyword>Post-essential thrombocythemia myelofibrosis</keyword>
	<keyword>RBC-transfusion-dependence</keyword>
	<keyword>Primary Myelofibrosis</keyword>
</DOC>